Coeptis Therapeutics Holdings expands technological initiatives

© Shutterstock

Wexford-based Coeptis Therapeutics Holdings, a biopharmaceutical company focused on pioneering cell therapy platforms, recently expanded its technological initiatives to include artificial intelligence (AI) and blockchain solutions.

The addition allows the company’s Technology Division to adapt to emerging trends, leverage new market opportunities and drive innovation that benefits customers and shareholders.

“We are thrilled to build upon the momentum we’ve generated with our Technology Division, particularly in the area of artificial intelligence, as we look to advance our initiatives leveraging blockchain technology,” Dave Mehalick, Coeptis president and CEO, said. “This expansion signifies not only our commitment to remaining at the forefront of technological developments but also our dedication to exploring new avenues that align with the rapidly evolving digital marketplace.”

Coeptis will explore the opportunities blockchain technology provides and believes AI has the potential to revolutionize the pharmaceutical industry.

Coeptis Therapeutics Holdings develops cell therapy platforms for autoimmune, cancer, and infectious diseases. Its Technology Division focuses on enhancing operational capabilities through advanced technologies to optimize business processes and improve efficiency.

The company’s therapeutic portfolio includes assets licensed from Washington-based Deverra Therapeutics including an allogeneic cellular immunotherapy platform and a unmodified natural killer cell therapy technology.

The company’s subsidiaries include Coeptis Therapeutics, Coeptis Pharmaceuticals, GEAR Therapeutics, and SNAP Biosciences.